ABSTRACT
The prevalence of food allergy (FA) is about 2-8 percent, with clinical manifestations ranging from localized symptoms, to severe anaphylactic reactions. FA is generally caused by milk, eggs, soybeans, tree nuts, peanuts, wheat, fish and crustacean; being peanut one of the main foods involved in Western countries. Although in other parts of the world peanut allergy (PA) is not a problem, probably due to timing of introduction into the diet, form and preparation, genetics, and the hygiene hypothesis. Unfortunately, in Chile there are no epidemiological data about FA or PA. A number of food allergens have been identified, which has improved patient diagnosis and treatment assessment. Regarding peanut, 9 allergens have been identified, Ara h 1 to Ara h 9 (Arachis hypogaea). The diagnosis of IgE-mediated PA is based on a consistent history and evidence of peanut-specific IgE sensitization, carried out by skin-prick testing or in vitro determination. PA treatment consists of peanuts avoidance, which often becomes difficult due to inadvertent consumption. Today promising treatments are under development, including oral induction tolerance or sublingual immunotherapy. These treatments offer the possibility of at least raising the threshold of the amount of peanut that would be necessary to cause a life-threatening allergic reaction.
Subject(s)
Humans , Male , Female , Peanut Hypersensitivity/diagnosis , Peanut Hypersensitivity/physiopathology , Peanut Hypersensitivity/therapy , Antigens, PlantABSTRACT
La esclerosis sistémica progresiva (ESP) es una enfermedad autoinmune crónica del tejido conectivo. Se caracteriza por una alteración vascular inicial, una respuesta inmune alterada con producción de autoanticuerpos y un exceso de síntesis y depósito de fibras de colágeno en la piel y tejido conectivo. La activación y el daño endotelial son eventos tempranos en la patogenia de la enfermedad; sin embargo, el factor gatillante continúa siendo desconocido. Se piensa que el evento principal sería la interacción entre eventos autoinmunes y cambios vasculares tempranos, lo cual resulta en la generación de fibroblastos activados considerados como las células efectoras de la enfermedad. Se reconocen dos subgrupos clínicos de ESP: la variedad cutánea limitada y la variedad cutánea difusa, las cuales presentan distintos patrones de compromiso orgánico, autoanticuerpos, evolución y sobrevida.
Progressive systemic sclerosis is a chronic autoimmune disease of connective tissue. It is characterized by early vascular changes, altered immune response with production of auto-antibodies, and excessive synthesis and deposition of collagen fibers in the skin and connective tissue. Activation and endothelial cell damage are early events in the pathogenesis of the disease, but the precise triggering event(s) remain elusive. The main event would be the interaction between autoimmune events early vascular changes, resulting in the generation of activated fibroblasts, regarded as effector cells of the disease. There are two major subgroups of SSc, the limited cutaneous and the diffuse cutaneous variety, which have distinct patterns of organ involvement, self-auto-antibodies, evolution and survival.